Today: 21 January 2026
Subscribe
Browse Category

NASDAQ:LULU News 21 January 2026

See-through “Get Low” leggings jolt Lululemon stock as quality questions return

See-through “Get Low” leggings jolt Lululemon stock as quality questions return

New York, January 21, 2026, 08:23 EST — Premarket Lululemon Athletica shares edged up about 0.3% in premarket trading Wednesday, rebounding slightly after a 6.5% drop the day before that pushed the stock to close at $188.76. The selloff came amid backlash over the company’s new “Get Low” workout line. (Morningstar) The online pause hits especially hard for Lululemon, given…
21 January 2026
·
Lululemon pulls new ‘Get Low’ leggings from online store after see-through complaints

Lululemon pulls new ‘Get Low’ leggings from online store after see-through complaints

Vancouver, Jan 21, 2026, 04:09 PST Lululemon Athletica halted online sales of its new “Get Low” workout line in North America on Tuesday after customers reported the leggings appeared see-through when bending or squatting. The product page also showed an error message. The company said it has “temporarily paused sales online” to review early feedback. Morningstar analyst David Swartz flagged…
21 January 2026
·
Lululemon pulls “Get Low” leggings from its website after sheer complaints, stock drops

Lululemon pulls “Get Low” leggings from its website after sheer complaints, stock drops

Vancouver, January 20, 2026, 15:28 PST Lululemon Athletica halted online sales of its new “Get Low” workout line in North America on Tuesday following customer complaints that the leggings became see-through when bending or squatting. The stock dropped roughly 6% that day. (Reuters) The setback is significant since Lululemon’s growth strategy depends heavily on premium products and rapid turnover in…
21 January 2026
··

Stock Market Today

  • Merck (MRK) Valuation Under Spotlight Amid Share Price Gains and Discounted Cash Flow Analysis
    January 21, 2026, 11:38 AM EST. Merck (MRK) shares last closed at $109.45, up 0.6% in one day and 8.27% over a month, highlighting positive momentum. The stock trades below the average analyst price target of $114.59 and at a price-to-earnings (P/E) ratio of 14.3x, which is below the US Pharmaceuticals sector average of 20.5x and peer average of 18.6x, suggesting undervaluation. A discounted cash flow (DCF) model estimates Merck's intrinsic value at $209.64 per share, implying a significant discount versus current price. However, risks like product setbacks and partnership changes remain. Investors face a question: is the market pricing in future challenges, or is the current valuation a genuine buying opportunity based on underlying fundamentals?
Go toTop